Literature DB >> 29473240

Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer.

Jing Zhang1, Ming Jin2, Xiaoyu Chen1, Rui Zhang1, Yanxia Huang1, Hui Liu1, Jinshui Zhu1.   

Abstract

OBJECTIVES: MicroRNAs (miRNAs) as small non-coding RNA molecules act by negatively regulating their target genes. Recent studies have shown that protein phosphatase Mg2+/Mn2+-dependent 1F (PPM1F) plays a critical role in cancer metastasis. But, the regulation mechanisms of PPM1F by miRNAs in gastric cancer (GC) remain undefined.
METHODS: The correlation of PPM1F or miR-590-3p (miR-590) expression with clinicopathological features and prognosis of the patients with GC was analysed by TCGA RNA-sequencing data. The miRNAs that target PPM1F gene were identified by bioinformatics and Spearman correlation analysis, and the binding site between miR-590 and PPM1F 3'UTR was confirmed by dual luciferase assay. MTT and Transwell assays were conducted to evaluate the effects of miR-590 or (and) PPM1F on cell proliferation and invasion.
RESULTS: We found that PPM1F expression was downregulated in GC tissues and cell lines and was correlated with tumour recurrence in patients with GC. The decreased expression of PPM1F was attributed to the dysregulation of miR-590 expression rather than its genetic or epigenetic alterations. Overexpression of miR-590 promoted cell proliferation and invasion capability of GC cells, while knockdown of miR-590 reversed these effects. Moreover, PPM1F was validated as a direct target of miR-590 and counteracted the tumour-promoting effects caused by miR-590. The expression of miR-590 presented the negative correlation with PPM1F expression and acted as an independent prognostic factor for tumour recurrence in patients with GC.
CONCLUSION: PPM1F may function as a suppressive factor and is negatively regulated by miR-590 in GC.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  PPM1F; gastric cancer; invasion; miR-590-3p; proliferation

Mesh:

Substances:

Year:  2018        PMID: 29473240      PMCID: PMC6528902          DOI: 10.1111/cpr.12444

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  30 in total

1.  MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.

Authors:  Sarah Jurmeister; Marek Baumann; Aleksandra Balwierz; Ioanna Keklikoglou; Aoife Ward; Stefan Uhlmann; Jitao David Zhang; Stefan Wiemann; Özgür Sahin
Journal:  Mol Cell Biol       Date:  2011-12-05       Impact factor: 4.272

2.  POPX adds to cell motility.

Authors:  Sheila Govind; Christine Hall
Journal:  Cell Cycle       Date:  2010-01-01       Impact factor: 4.534

3.  POPX2 phosphatase regulates cell polarity and centrosome placement.

Authors:  Jing-Ling Hoon; Hoi-Yeung Li; Cheng-Gee Koh
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

4.  MiR-429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl-2.

Authors:  Ping Zhu; Jingping Zhang; Jianfei Zhu; Jun Shi; Qiuwei Zhu; Yuanyuan Gao
Journal:  Cell Physiol Biochem       Date:  2015-10-30

5.  Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family.

Authors:  Fengju Song; Da Yang; Ben Liu; Yan Guo; Hong Zheng; Lian Li; Tao Wang; Jinpu Yu; Yanrui Zhao; Ruifang Niu; Han Liang; Hans Winkler; Wei Zhang; Xishan Hao; Kexin Chen
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

6.  Investigation of POPX2 phosphatase functions by comparative phosphoproteomic analysis.

Authors:  Pritpal Singh; Chee Sian Gan; Tiannan Guo; Hui-Qun Phang; Siu Kwan Sze; Cheng Gee Koh
Journal:  Proteomics       Date:  2011-06-08       Impact factor: 3.984

7.  MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer.

Authors:  Chunlin Ou; Zhenqiang Sun; Xiayu Li; Xiaoling Li; Weiguo Ren; Zailong Qin; Xuemei Zhang; Weitang Yuan; Jia Wang; Wentao Yu; Shiwen Zhang; Qiu Peng; Qun Yan; Wei Xiong; Guiyuan Li; Jian Ma
Journal:  Cancer Lett       Date:  2017-04-19       Impact factor: 8.679

8.  MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulation.

Authors:  L Liu; Y Wang; R Bai; K Yang; Z Tian
Journal:  Oncogenesis       Date:  2016-05-09       Impact factor: 7.485

9.  MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis.

Authors:  Qingxin Zhou; Yuekun Zhu; Xiaoli Wei; Jianhua Zhou; Liang Chang; Hong Sui; Yu Han; Daxun Piao; Ruihua Sha; Yuxian Bai
Journal:  Cell Death Dis       Date:  2016-10-13       Impact factor: 8.469

10.  Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway.

Authors:  Jia-Xing Zhang; Yi Xu; Ying Gao; Cui Chen; Zhou-San Zheng; Miao Yun; Hui-Wen Weng; Dan Xie; Sheng Ye
Journal:  Mol Cancer       Date:  2017-01-23       Impact factor: 27.401

View more
  12 in total

1.  Hsa-MiR-590-3p Promotes the Malignancy Progression of Pancreatic Ductal Carcinoma by Inhibiting the Expression of p27 and PPP2R2A via G1/S Cell Cycle Pathway.

Authors:  Xiaoyang Shi; Weiwei Sheng; Chao Jia; Jingtong Tang; Ming Dong
Journal:  Onco Targets Ther       Date:  2020-10-29       Impact factor: 4.147

2.  NOL6, a new founding oncogene in human prostate cancer and targeted by miR-590-3p.

Authors:  Degang Dong; Mei Song; Xiaoli Wu; Wanchun Wang
Journal:  Cytotechnology       Date:  2020-04-05       Impact factor: 2.058

3.  Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer.

Authors:  Jing Zhang; Ming Jin; Xiaoyu Chen; Rui Zhang; Yanxia Huang; Hui Liu; Jinshui Zhu
Journal:  Cell Prolif       Date:  2018-02-22       Impact factor: 6.831

4.  MicroRNA-4268 inhibits cell proliferation via AKT/JNK signalling pathways by targeting Rab6B in human gastric cancer.

Authors:  Lingyu Zhao; Meng Xue; Lu Zhang; Bo Guo; Yannan Qin; Qiuyu Jiang; Ruifang Sun; Juang Yang; Lumin Wang; Liying Liu; Xiaofei Wang; Chen Huang; Dongdong Tong
Journal:  Cancer Gene Ther       Date:  2019-07-15       Impact factor: 5.987

5.  Exosomal LINC00161 promotes angiogenesis and metastasis via regulating miR-590-3p/ROCK axis in hepatocellular carcinoma.

Authors:  Li-Na You; Qin-Wen Tai; Lin Xu; Yi Hao; Wen-Jia Guo; Qiao Zhang; Qing Tong; Heng Zhang; Wu-Kui Huang
Journal:  Cancer Gene Ther       Date:  2021-01-07       Impact factor: 5.987

6.  CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression.

Authors:  Hongjian Wang; Wei Chen; Ming Jin; Lidan Hou; Xiaoyu Chen; Rui Zhang; Jing Zhang; Jinshui Zhu
Journal:  Mol Cancer       Date:  2018-11-23       Impact factor: 27.401

7.  Inhibition of the aberrant A1CF-FAM224A-miR-590-3p-ZNF143 positive feedback loop attenuated malignant biological behaviors of glioma cells.

Authors:  Yichen Song; Lianqi Shao; Yixue Xue; Xuelei Ruan; Xiaobai Liu; Chunqing Yang; Jian Zheng; Shuyuan Shen; Jiajia Chen; Zhen Li; Yunhui Liu
Journal:  J Exp Clin Cancer Res       Date:  2019-06-11

8.  Long noncoding RNA ZFAS1 promotes progression of papillary thyroid carcinoma by sponging miR-590-3p and upregulating HMGA2 expression.

Authors:  Houchao Tong; Xi Zhuang; Jingsheng Cai; Yu Ding; Yan Si; Hao Zhang; Meiping Shen
Journal:  Onco Targets Ther       Date:  2019-09-13       Impact factor: 4.147

9.  CircDUSP16 promotes the tumorigenesis and invasion of gastric cancer by sponging miR-145-5p.

Authors:  Zizhen Zhang; Chaojie Wang; Yeqian Zhang; Site Yu; Gang Zhao; Jia Xu
Journal:  Gastric Cancer       Date:  2019-11-27       Impact factor: 7.370

10.  Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma.

Authors:  Xiao-Yu Chen; Jing Zhang; Li-Dan Hou; Rui Zhang; Wei Chen; Hui-Ning Fan; Yan-Xia Huang; Hui Liu; Jin-Shui Zhu
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.